AASLD与IDSA慢性乙型肝炎治疗实践指南
该指南由AASLD与IDSA采用GRADE方法制定,遵循美国国家医学院标准,通过PICO框架提出6个问题,涵盖乙型肝炎母婴传播与水平传播的预防、合并HCV/HDV/HIV感染及HBsAg清除后肝癌监测、免疫耐受或不确定期治疗及抗病毒停药,基于4项系统综述与2项现有系统综述形成推荐。
要点
- 指南聚焦CHB预防、肝癌监测和治疗三大领域。
- 采用GRADE方法及PICO框架提出6个结构化问题。
- 推荐基于4项系统综述和2项现有系统综述的证据。
核心结论
- 该循证指南为优化慢性乙型肝炎患者管理提供更新推荐。
研究设计与样本
- 指南由AASLD与IDSA制定,遵循美国国家医学院标准并采用GRADE方法。
主要发现
- 指南小组通过PICO框架提出6个问题,涉及预防、肝癌监测和治疗。
关键数值与推荐
- 预防涵盖乙型肝炎母婴传播和水平传播。
- 肝癌监测涵盖HBsAg阳性合并HCV、HDV和/或HIV感染者及HBsAg清除后人群。
- 治疗涵盖HBsAg阳性免疫耐受期或不确定期患者及抗病毒治疗停药。
临床怎么用
- 临床可依据该指南推荐优化CHB患者的预防、监测与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. METHODS: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. CONCLUSIONS: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
引用
- Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2025. PMID: 41186418. doi:10.1097/HEP.0000000000001549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。